BOTHELL, Wash., March 06, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate in a fireside chat at the Zacks SCR Life Sciences Virtual Investor Forum on Thursday, March 13, 2025 at 11:30 a.m. Eastern time (8:30 a.m. Pacific time). The fireside chat will be hosted by Zacks Small Cap Research Senior Analyst David Bautz, PhD.
Pre-register for Cocrystal’s virtual presentation is available on the Cocrystal website here. Investors will have the opportunity to submit questions online during the live event and can request a one-on-one meeting with management by selecting the “Book A Meeting” button on Cocrystal’s presentation page. A replay of the event will be available on the Cocrystal website here.
About Virtual Investor Conferences®
Virtual Investor Conferences is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. Learn more about the event at www.virtualinvestorconferences.com.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.
Contact:
Alliance Advisors IR
Jody Cain
310-691-7100
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.17 |
Daily Change: | -0.10 -7.54 |
Daily Volume: | 31,774 |
Market Cap: | US$11.850M |
March 31, 2025 December 31, 2024 November 13, 2024 September 26, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load